Virulence properties of type VII Streptococcus agalactiae (group B streptococci) and immunochemical analysis of capsular type polysaccharide

Journal of Medical Microbiology

Volumn 48, Issue 11, 1999, Pages 983-990

  Von Hunolstein, Christina ^e   Parisi, Laura ^e   Tissi, Luciana ^a   Recchia, Simona ^e   Alfarone, Giovanna ^e   Nicolini, Laura ^b   Volpe, Corrado ^b   Wagner, Barbara ^c   Motlovà, Jitka ^d   Orefici, Graziella ^e  

^a UNIVERSITY OF PERUGIA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE;

ARTICLE; BACTERIAL MEMBRANE; BACTERIAL VIRULENCE; IMMUNOCHEMISTRY; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE;

EID: 0033493817     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/00222615-48-11-983     Document Type: Article

References (42)

1. 1. Baker CJ, Edwards MS. Group B streptococcal infections. In: Remington JS, Klein JO (eds) Infectious diseases of the fetus & newborn infant, 4th edn. Philadelphia, WB Saunders. 1995: 980-1054.
2. 2. Schuchat, A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 1998; 3: 497-513.
3. 3. Harrison LH, Ali A, Dwyer DM et al. Relapsing invasive group B streptococcal infection in adults. Ann Intern Med 1995; 123: 421-427.
4. 4. Farley MM, Harvey RC, Stull T el al. A population-based assessment of invasive disease due to group B Streptococcus in nonpregnant adults. N Engl J Med 1993; 328: 1807-1811.
5. 5. Lancefield RC. A serological differentiation of specific types of bovine hemolytic streptococci (group B). J Exp Med 1934; 59: 441-458.
6. 6. Wilkinson HW. Nontypable group B streptococci isolated from human sources. J Clin Microbiol 1977; 6: 183-184.
7. 7. Perch B, Kjems E, Henrichsen J. New serotypes of group B streptococci isolated from human sources. J Clin Microbiol 1979; 10: 109-110.
8. 8. Murai T, Mochida T. Further study of prevalence on group B Streptococcus, strain JM9 in Japan. Pathogenic streptococci: present and future. St Petersburg, Russia, Lancer Publication. 1994; 343-344.
9. 9. Wessels MR, Benedi V-J, Jennings HJ, Michon F, DiFabio JL, Kasper DL. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun 1989; 57: 1089-1094.
10. 10. Wessels MR, DiFabio JL, Benedi VJ et al. Structural determination and immunochemical characterization of type V group B Streptococcus capsular polysaccharide. J Biol Chem 1991; 266: 6714-6719.
11. 11. von Hunolstein C, D'Ascenzi S, Wagner B et al. Immunochemistry of capsular type polysaccharide and virulence properties of type VI Streptococcus agalactiae (group B streptococci). Infect Immun 1993; 61: 1272-1280.
12. 12. Kogan G, Brisson JR, Kasper DL, von Hunolstein C, Orefiei G, Jennings HJ. Structural elucidation of the novel type VII group B Streptococcus capsular polysaccharide by high resolution NMR spectroscopy. Carbohydr Res 1995; 277: 1-9.
13. 13. Kogan G, Uhrin D, Brisson JR et al. Structural and immunochemical characterization of the type VIII group B streptococcus capsular polysaccharide. J Biol Chem 1996; 271: 8786-8790.
14. 14. Jelínková J, Motlová J. Worldwide distribution of two new serotypes of group B streptococci: type IV and provisional type V. J Clin Microbiol 1985; 21: 361-362.
15. 15. Wagner M, Murai T, Wagner B, Gunther E, Jelínková J. JM9 strains, a new type of group B streptococci from Japan. Int J Med Microbiol Virol Parasitol Infect Dis 1994; 280: 488-496.
16. 16. Blumberg HM, Stephens DS, Modansky M et al. Invasive group B streptococcal disease: the emergence of serotype V. J Infect Dis 1996; 173: 365-373.
17. 17. Feng-Ying CL, Clemens JD, Azimi PV et al. Capsular polysaccharide types of group B streptococcal isolates from neonates with early-onset systemic infection. J Infect Dis 1998; 177: 790-792.
18. 18. Ouchterlony O. Diffusion in gel methods for immunological analysis. Prog Allergy 1958; 5: 1-78.
19. 19. Grabar P, Williams CA. Méthode permettant l'étudé conjuguée des propriétés électrophorétiques et immunochimiques d'un mélange de protéines. Application au sérum sanguin. Biochim Biophys Acta 1953; 10: 193-194.
20. 20. Wagner B, Atrat PG, Clark-Curtiss LE, Wagner M. Localization of the steroid 1-dehydrogenase in Rhodococcus erythropolis IMET7030 by immunoelectron microscopy. J Basic Microbiol 1992; 32: 65-71.
21. 21. von Hunolstein C, Nicolini L, D'Ascenzi S, Volpe C, Alfarone G, Orefici G. Sialic acid and biomass production by Streptococcus agalactiae under different growth conditions. Appl Microbiol Biotechnol 1993; 38: 458-462.
22. 22. Tissi L, Marconi P, Mosci P et al. Experimental model of type IV Streptococcus agalactiae (group B Streptococcus) infection in mice with early development of septic arthritis. Infect Immun 1990; 58: 3093-3100.
23. 23. Reed LJ, Muench H. A simple method of estimating fifty per cent endpoints. Am J Hyg 1938; 27: 493-497.
24. 24. Tissi L, von Hunolstein C, Mosci P, Campanelli C, Bistoni F, Orefici G. In vivo efficacy of azithromycin in treatment of systemic and septic arthritis induced by type IV group B Streptococcus strains in mice: comparative study with erythromycin and penicillin G. Antimicrob Agents Chemother 1995; 39: 1938-1947.
25. 25. Wibawan IW, Lämmler CH, Lautrou Y, Warsa UCH. Serotyping and further characterization of group B streptococcal isolates from Indonesia. Int J Med Microbiol Virol Parasitol Infect Dis 1992; 277: 260-266.
26. 26. Ferrieri P, Cho DS, Flores AE. Identification of uncommon group B streptococcal serotypes and characterization of nontypable clinical isolates. Abstract of the Lancefield Society Meeting, San Francisco, CA, 17 September, 1995.
27. 27. Tissi L, von Hunolstein C, Bistoni F, Marangi M, Parisi L, Orefici G. Role of group B streptococcal capsular polysaccharide in the induction of septic arthritis. J Med Microbiol 1998; 47: 717-723.
28. 28. Jennings HJ, Katzenellenbogen E, Lugowski C, Michon F, Roy R, Kasper DL. Structure, conformation and immunology of sialic acid-containing polysaccharides of human pathogenic bacteria. Pure Appl Chem 1984; 56: 893-905.
29. 29. Wilkinson HW, Moody MD. Serological relationships of type 1 antigens of group B streptococci. J Bacteriol 1969; 97: 629-634.
30. 30. Jennings HJ, Rosell KG, Kasper DL. Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus. Can J Biochem 1980; 58: 112-120.
31. 31. Jennings HJ, Lugowski C, Kasper DL. Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide. Biochemistry 1981; 20: 4511-4518.
32. 32. Kasper DL, Baker CJ, Galdes B, Katzenellenbogen E, Jennings HJ. Immunochemical analysis and immunogenicity of the type II group B streptococcal capsular polysaccharide. J Clin Invest 1983; 72: 260-269.
33. 33. Schifferle RE, Jennings HJ, Wessels MR, Katzenellenbogen E, Roy R, Kasper DL. Immunochemical analysis of the types Ia and Ib group B streptococcal polysaccharides. J Immunol 1985; 135: 4164-4170.
34. 34. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith JCP. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroup B and C with carbon 13 nuclear magnetic resonance. J Biol Chem 1975; 250: 1926-1932.
35. 35. Baltimore RS, Kasper DL, Baker CJ, Goroff DK. Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci. J Immunol 1977; 118: 673-678.
36. 36. Shigeoka AO, Pincus SH, Rote NS, Hill HR. Protective efficacy of hybridoma type-specific antibody against experimental infection with group-B Streptococcus. J Infect Dis 1984; 149: 363-372.
37. 37. Teti G, Calapai M, Calogero G et al. Specificity and protective activity of murine monoclonal antibodies directed against the capsular polysaccharide of type III group B streptococci. Hybridoma 1992; 11: 13-22.
38. 38. Ricci ML, von Hunolstein C, Gomez MJ, Parisi L, Tissi L, Orefici G. Protective activity of a murine monoclonal antibody against acute and chronic experimental infection with type IV group B Streptococcus. J Med Microbiol 1996; 44: 475-481.
39. 39. Elliott JA, Farmer KD, Facklam RR. Sudden increase in isolation of group B streptococci, serotype V, is not due to emergence of a new pulsed-field gel electrophoresis type. J Clin Microbiol 1998; 36: 2115-2116.
40. 40. Harrison LH, Elliott JA, Dwyer DM et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. J Infect Dis 1998; 177: 998-1002.
41. 41. Kvam AI, Efstratiou A, Bevanger L et al. Distribution of serovariants of group B streptococci in isolates from England and Norway. J Med Microbiol 1995; 42: 246-250.
42. 42. Paoletti LC, Wessels MR, Kasper DL. Optimization of group-B streptococcal glycoconjugate vaccines. In: Chanock MR, Brown F, Ginsberg HF, Norrby E (eds) Vaccines 95. Molecular appoachcs to the control of infectious diseases. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press. 1995: 213-217.